Impact of Hepatitis B and C Virus Infections on Kidney Transplantation: A Single Center Experience

Abstract

Objective. The impacts of hepatitis C virus (HCV) and hepatitis B virus (HBV) infections on patient and renal graft survivals are controversial. This study sought to evaluate the effects of pretransplantation HCV and HBV infections on renal transplant patients and their grafts at our center. Patients and Methods. We retrospectively examined 1224 renal transplantations performed between 1992 and 2006, including 28 HBsAg positive; 64, anti-HCV; 9, anti-HCV plus HBsAg positive; and 1123, negative for anti-HCV and HBsAg. The mean posttransplantation follow-up was 5.6 Ϯ 4.1 years.Results. The prevalences of HBV infection were 6.2% in 1994 and 2.3% in 2006 and those of HCV infection were 6.8% in 1998 and 5.2% in 2006. The rejection rate was higher among HBVϩ (46.4%) and HCVϩ (40.6%) groups than the negative groups (31.5%), but it was not significant. There were no significant differences in patient and graft survivals among the groups. The major cause of patient death was liver failure among patients with concomitant HBVϩ and HCVϩ infections and cardiovascular disease among HCVϩ and negative patients. Conclusions. There has been a decrease in the prevalence of recipients with hepatitis virus infections over the last 15 years. Patient and graft survivals were not affected by HCV or HBV infection.

The impact of hepatitis C virus infection on long-term outcome in renal transplant patients

“…While some studies reported an increased rate of rejection (20,21), others concluded that there was no significant difference (22). In our study, there were similar overall rates of rejection episodes in the anti-HCV-positive and -negative groups.…”

“…Hepatitis C virus and renal transplantation 169 survivals (1,16,22). Our study revealed that there was no difference in patient survival between anti-HCV-positive and -negative groups over the 10-year study period, but graft survival was shorter in the 10 th year in the anti-HCV-positive group.…”

Use of New Direct-Acting Antivirals (DAAs) in Renal Transplant Patients Infected with Hepatitis C Virus: The First Experience in Sub-Saharan Africa

“…In developed countries around 1.8 to 8% of renal transplant patients are infected with HCV [1,2]. Indeed, prior to the era of the new direct acting antivirals (DAAs), the treatment of hepatitis C was based solely on the combination of standard interferon and ribavirin.…”

Management of Chronic Hepatitis B in Special Populations: Immunosuppressed Patients and Chronic Kidney Disease

“…Pre-therapy HBV DNA was 6.3 and 8.68 Log 10 Eq/mL by branched DNA assay (bDNA assay) respectively, with detectable HBeAg in serum. ADV-based therapy was given for a median time of 15 months (range = [3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19]. A significant reduction of serum HBV DNA occurred without changes in the HBeAg serologic status.…”